Core Viewpoint - Yiming Oncology (01541) has terminated its licensing agreement with Axion Bio, Inc., regaining global development and commercialization rights for two core anti-cancer drugs, IMM2510 and IMM27M, while retaining the previously received $35 million upfront and milestone payments [1] Group 1: Agreement Termination - The collaboration with Axion was initially established on August 1, 2024, granting Axion exclusive rights for the development and commercialization of IMM2510 and IMM27M outside Greater China [1] - The termination agreement allows Axion limited rights to gradually conclude its related clinical development activities [1] Group 2: Drug Details - IMM2510 is a bispecific molecule targeting VEGF/PD-L1, utilizing mAb-Trap structure to inhibit tumor angiogenesis and activate immune cells, creating an anti-tumor synergistic effect [1] - IMM27M is a next-generation CTLA-4 monoclonal antibody with enhanced ADCC activity, capable of eliminating immunosuppressive regulatory T cells in the tumor microenvironment, thereby strengthening T cell anti-tumor responses [1] Group 3: Future Development - Yiming Oncology expresses confidence in the therapeutic potential of both drugs and plans to accelerate their clinical development process [1]

Group 1 - The core point of the news is that Haichuang Pharmaceutical has launched its self-developed Class I anti-cancer drug, Deuteroenzalutamide soft capsules, which are now available nationwide for patients with metastatic castration-resistant prostate cancer [1][2] - The drug is specifically designed for adult patients who have progressed after treatment with Abiraterone acetate and chemotherapy, and who have not previously received new androgen receptor inhibitors [1] - Prostate cancer is the second most common cancer among men globally, with 1.467 million new cases reported in 2022, and China saw 134,000 new cases in the same year, indicating a rising trend in incidence [1] Group 2 - Deuteroenzalutamide soft capsules are the first innovative drug approved in China for patients with metastatic castration-resistant prostate cancer, highlighting its clinical significance and urgent demand [1][2] - The company emphasizes its commitment to ensuring the quality and stable supply of the drug while accelerating the development of its rich pipeline of innovative therapies for global patients [2] - The drug reportedly shows superior safety compared to other endocrine therapies, significantly reducing the incidence of central nervous system adverse events and common complications in elderly patients [1]